Synthetic Biologist Aims to Create Pig with Human Lungs
By Lisa M. Krieger,
San Jose Mercury News
| 11. 14. 2014
Untitled Document
SAN FRANCISCO -- In a provocative cross-species experiment, scientists are striving to rewrite the pig genome so the animal grows lungs that could be transplanted into humans.
"We are re-engineering the pig, changing its genetic code," said genome pioneer Craig Venter at SynBioBeta 2014, an annual synthetic biology conference in San Francisco. "If we succeed with rewriting the pig genome, we will have replacement organs for those who need them," he said Friday.
His team at Synthetic Genomics is designing the project, he said, creating on computers the code needed to build the hybrid. By changing as few as five genes, they have created lungs that survived for a year in baboons, he said.
In other major news at the conference, Google confirmed that Stanford University bioengineer Drew Endy has joined its team at the secretive Google X, which created such projects as Google Glass, driverless cars and high-altitude Wi-Fi balloons.
The hiring of Endy, brought to Stanford's School of Engineering from the Massachusetts Institute of Technology, suggests that Google seeks to explore the design and construction of...
Related Articles
By Grace Won, KQED [with CGS' Katie Hasson] | 12.02.2025
In the U.S., it’s illegal to edit genes in human embryos with the intention of creating a genetically engineered baby. But according to the Wall Street Journal, Bay Area startups are focused on just that. It wouldn’t be the first...
Several recent Biopolitical Times posts (1, 2, 3, 4) have called attention to the alarmingly rapid commercialization of “designer baby” technologies: polygenic embryo screening (especially its use to purportedly screen for traits like intelligence), in vitro gametogenesis (lab-made eggs and sperm), and heritable genome editing (also termed embryo editing or reproductive gene editing). Those three, together with artificial wombs, have been dubbed the “Gattaca stack” by Brian Armstrong, CEO of the cryptocurrency company...
By Adam Feuerstein, Stat | 11.20.2025
The Food and Drug Administration was more than likely correct to reject Biohaven Pharmaceuticals’ treatment for spinocerebellar ataxia, a rare and debilitating neurodegenerative disease. At the very least, the decision announced Tuesday night was not a surprise to anyone paying attention. Approval...
By Lucy Tu, The Guardian | 11.05.2025
Beth Schafer lay in a hospital bed, bracing for the birth of her son. The first contractions rippled through her body before she felt remotely ready. She knew, with a mother’s pit-of-the-stomach intuition, that her baby was not ready either...
